Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination among Adults in the USA Aged 50–59 Years at Increased Risk of Severe RSV Disease
Modeling demonstrates health benefits of adjuvanted rsvpref3 vaccination in adults aged 50-59, highlighting its cost-effectiveness.
Key Points
Adjuvanted rsvpref3 vaccination prevented over 163,000 RSV illness cases in high-risk adults over five years, indicating significant public health benefits.
The intervention was deemed cost-saving, improving health outcomes with a dominant strategy over no vaccination among adults with chronic obstructive pulmonary disease.
Modeling included over 3.3 million adults aged 50-59 with comorbidities, confirming the vaccination's effectiveness based on literature and expert consultation.
Implementing vaccination access is crucial for populations at increased risk of severe RSV disease, pointing to the need for public health efforts.